MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma Stocks
Indian Pharma
Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
Last 2 Days: Discover India's #1 defence stock now
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 748.75 -0.09% | 750.30 0.33% |
|
More Info
|
| AJANTA PHARMA | 1,598.85 -2.20% | 1,605.95 -1.34% |
|
More Info
|
| ALEMBIC PHARMA | 973.70 -3.75% | 973.75 -3.79% |
|
More Info
|
| BIOCON | 417.20 -2.86% | 417.20 -2.90% |
|
More Info
|
| CADILA HEALTHCARE | 423.85 -0.36% | 424.30 -0.32% |
|
More Info
|
| CIPLA | 756.85 -0.07% | 757.55 0.01% |
|
More Info
|
| DIVIS LABORATORIES | 3,067.25 -0.60% | 3,068.85 -0.80% |
|
More Info
|
| DR. REDDYS LAB | 5,015.90 -0.15% | 5,018.25 -0.07% |
|
More Info
|
| GLENMARK PHARMA | 485.00 -0.38% | 485.45 -0.35% |
|
More Info
|
| INDOCO REMEDIES | 255.10 -1.54% | 255.10 -1.77% |
|
More Info
|
| IPCA LABS | 2,173.00 0.90% | 2,175.40 0.92% |
|
More Info
|
| J.B.CHEMICALS | 999.85 -3.29% | 999.35 -2.77% |
|
More Info
|
| LUPIN | 990.75 -0.20% | 991.45 -0.19% |
|
More Info
|
| NATCO PHARMA | 919.90 0.79% | 920.05 0.88% |
|
More Info
|
| NIFTY 50 | Not Listed | 11,930.35 0.28% |
|
More Info
|
| ORCHID PHARMA | 5.25 -4.89% | 18.90 -2.83% |
|
More Info
|
| PANACEA BIOTECH | 180.20 -0.36% | 180.00 -0.58% |
|
More Info
|
| PIRAMAL ENTERPRISES | 1,327.45 0.58% | 1,327.15 0.49% |
|
More Info
|
| S&P BSE HEALTHCARE | 19,637.28 -0.17% | Not Listed |
|
More Info
|
| S&P BSE SENSEX | 40,685.50 0.31% | Not Listed |
|
More Info
|
| STRIDES PHARMA SCIENCE | 743.45 1.87% | 743.10 1.92% |
|
More Info
|
| SUN PHARMA | 484.35 -0.27% | 484.50 -0.22% |
|
More Info
|
| TORRENT PHARMA | 2,734.35 0.74% | 2,733.75 0.69% |
|
More Info
|
| WOCKHARDT | 294.95 0.39% | 294.60 0.37% |
|
More Info
|
BSE prices: October 23, 2020 (Close) NSE prices: October 23, 2020 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 11,493.6 (down 0.5%). The index is up 11.6% over the last 30 days. And over the last 1 year, it has gained 22.3%.
Within the Indian Pharma sector, the top gainers were STRIDES PHARMA SCIENCE (up 1.9%) and IPCA LABS (up 0.9%). On the other hand, ALEMBIC PHARMA (down 3.8%) and J.B.CHEMICALS (down 3.3%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 11,930.4 (up 0.3%).
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
Today's Market
Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)
Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.
Related Views on News
ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)
Oct 23, 2020 | Updated on Oct 23, 2020For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)
Sep 29, 2020 | Updated on Sep 29, 2020For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)
Oct 10, 2019 | Updated on Oct 10, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
More Views on NewsMost Popular
My View on ITC (Fast Profits Daily)
Oct 23, 2020What do the charts say about ITC?
The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)
Oct 12, 2020Is ITC an investment or a speculation at current levels?
Why ITC and not HUL is my Idea of a Good Investment Right Now 
(Views On News)
Oct 15, 2020
Rahul Shah discusses HUL's lost decade and its implications for ITC.
Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)
Oct 16, 2020My research on India's leading defence companies brought me to one major player in drone manufacturing.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
S&P BSE HEALTHCARE
Oct 23, 2020 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.